Neurocrine (NBIX) Stock Forecast & Price Target

Compare

1,462 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

NBIX Analyst Ratings

Strong Buy

22 Buy

3 Hold

0 Sell

Based on 25 analysts giving stock ratings to

Neurocrine

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

NBIX Stock 12 Month Forecast

Average Price Target

$168.73

▲(15.04% Upside)

Based on 25 Wall Street analysts offering 12 month price targets for Neurocrine in the last 3 months. The average price target is $168.73 with a high forecast of $200.00 and a low forecast of $124.00. The average price target represents a 15.04% change from the last price of $146.67.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"105":"$105","129":"$129","153":"$153","177":"$177","201":"$201"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":200,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$200.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":168.73,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$168.73</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":124,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$124.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[105,129,153,177,201],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,141.92,146.3876923076923,150.8553846153846,155.3230769230769,159.79076923076923,164.25846153846152,168.72615384615384,173.19384615384615,177.66153846153844,182.12923076923076,186.59692307692308,191.06461538461537,195.53230769230768,{"y":200,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,141.92,143.98230769230767,146.04461538461538,148.10692307692307,150.16923076923075,152.23153846153846,154.29384615384615,156.35615384615383,158.41846153846154,160.48076923076923,162.5430769230769,164.6053846153846,166.6676923076923,{"y":168.73,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,141.92,140.54153846153844,139.16307692307691,137.78461538461536,136.40615384615384,135.0276923076923,133.64923076923077,132.27076923076922,130.8923076923077,129.51384615384615,128.13538461538462,126.75692307692307,125.37846153846154,{"y":124,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":127.06,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":114.15,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 51,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":122.21,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":125.89,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":136.5,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":151.82,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 51,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":118.72,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":107,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":106.59,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":124.56,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":128,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 62,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":128.91,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":141.92,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 53,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$200.00

Average Price Target$168.73

Lowest Price Target$124.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Marc Goodman

Leerink Partners

―

Buy

―

Reiterated

09/23/25

Leerink Partners Remains a Buy on Neurocrine (NBIX)We remain Outperform.

Myles Minter

William Blair

―

Buy

―

Reiterated

09/22/25

Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (NASDAQ: PVLA) and Neurocrine (NASDAQ: NBIX)We believe osavampator’s safety profile is clearly differentiated from prior orthosteric agonist approaches developed by Eli Lilly (LY 451646 [LLY $751.99]), Biogen (BIIB 104 [BIIB $142.50; Outperform]), and GSK (GSK 729327 [GSK $40.67]). We note that Draig Therapeutics (private) recently launched (see here) and plans to commence a Phase II clinical trial in MDD for DT-101, another AMPA receptor after successfully completing a Phase Ia trial in 60 subjects demonstrating safety and target engagement.

Ami Fadia

Needham

$161→$170

Buy

15.91%

Upside

Assigned

09/22/25

Neurocrine's Osavampator Shows Promising Phase 2 Results, Boosting Buy Rating and Stock Price TargetWe increase our PoS for osavampator (30% to 45%) and raise our PT to $170. Reiterate Buy.

Danielle Brill

Truist Financial

―

Buy

―

Reiterated

09/22/25

Truist Financial Sticks to Their Buy Rating for Neurocrine (NBIX)

Akash Tewari

Jefferies

$160→$169

Buy

15.22%

Upside

Reiterated

09/22/25

Neurocrine price target raised to $169 from $160 at JefferiesNeurocrine price target raised to $169 from $160 at Jefferies

Paul Matteis

Stifel Nicolaus

$174

Buy

18.63%

Upside

Reiterated

09/22/25

Analysts Are Bullish on These Healthcare Stocks: Nuvalent (NUVL), Neurocrine (NBIX)

David Amsellem

Piper Sandler

$175

Buy

19.32%

Upside

Reiterated

09/22/25

Neurocrine (NBIX) Receives a Buy from Piper Sandler

Evan Seigerman

BMO Capital

$124

Hold

-15.46%

Downside

Reiterated

09/22/25

BMO Capital Sticks to Its Hold Rating for Neurocrine (NBIX)BMO Capital analyst Evan David Seigerman reiterated a Market Perform rating and $124.00 price target on Neurocrine Bio. (NASDAQ: NBIX).

Tazeen Ahmad

Bank of America Securities

$191

Buy

30.22%

Upside

Reiterated

09/22/25

Promising Phase 2 Results and Safety Profile of Osavampator Justify Buy Rating for Neurocrine Biosciences

Sean Laaman

Morgan Stanley

$163

Buy

11.13%

Upside

Reiterated

09/21/25

Promising Potential of Neurocrine's Osavampator in Treating Major Depressive Disorder: A Buy Recommendation by Sean Laaman

Ashwani Verma

UBS

$174→$188

Buy

28.18%

Upside

Reiterated

09/21/25

Neurocrine (NBIX) Receives a Buy from UBS

Cory Kasimov

Evercore ISI

$200

Buy

36.36%

Upside

Reiterated

09/19/25

Evercore ISI Sticks to Their Buy Rating for Neurocrine (NBIX)

Brian Abrahams

RBC Capital

$144→$149

Buy

1.59%

Upside

Reiterated

09/05/25

Neurocrine (NBIX) Receives a Buy from RBC Capital

Joshua Schimmer

Cantor Fitzgerald

$170

Buy

15.91%

Upside

Reiterated

09/04/25

Neurocrine (NBIX) Receives a Buy from Cantor Fitzgerald

Bryce Generon

TR | OpenAI - 4o

$145→$152

Buy

3.63%

Upside

Reiterated

08/19/25

AI Generated ArticleAI Generated Article

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Marc Goodman

Leerink Partners

―

Buy

―

Reiterated

09/23/25

Leerink Partners Remains a Buy on Neurocrine (NBIX)We remain Outperform.

Myles Minter

William Blair

―

Buy

―

Reiterated

09/22/25

Ami Fadia

Needham

$161→$170

Buy

15.91%

Upside

Assigned

09/22/25

Neurocrine's Osavampator Shows Promising Phase 2 Results, Boosting Buy Rating and Stock Price TargetWe increase our PoS for osavampator (30% to 45%) and raise our PT to $170. Reiterate Buy.

Danielle Brill

Truist Financial

―

Buy

―

Reiterated

09/22/25

Truist Financial Sticks to Their Buy Rating for Neurocrine (NBIX)

Akash Tewari

Jefferies

$160→$169

Buy

15.22%

Upside

Reiterated

09/22/25

Neurocrine price target raised to $169 from $160 at JefferiesNeurocrine price target raised to $169 from $160 at Jefferies

Paul Matteis

Stifel Nicolaus

$174

Buy

18.63%

Upside

Reiterated

09/22/25

Analysts Are Bullish on These Healthcare Stocks: Nuvalent (NUVL), Neurocrine (NBIX)

David Amsellem

Piper Sandler

$175

Buy

19.32%

Upside

Reiterated

09/22/25

Neurocrine (NBIX) Receives a Buy from Piper Sandler

Evan Seigerman

BMO Capital

$124

Hold

-15.46%

Downside

Reiterated

09/22/25

BMO Capital Sticks to Its Hold Rating for Neurocrine (NBIX)BMO Capital analyst Evan David Seigerman reiterated a Market Perform rating and $124.00 price target on Neurocrine Bio. (NASDAQ: NBIX).

Tazeen Ahmad

Bank of America Securities

$191

Buy

30.22%

Upside

Reiterated

09/22/25

Promising Phase 2 Results and Safety Profile of Osavampator Justify Buy Rating for Neurocrine Biosciences

Sean Laaman

Morgan Stanley

$163

Buy

11.13%

Upside

Reiterated

09/21/25

Promising Potential of Neurocrine's Osavampator in Treating Major Depressive Disorder: A Buy Recommendation by Sean Laaman

Ashwani Verma

UBS

$174→$188

Buy

28.18%

Upside

Reiterated

09/21/25

Neurocrine (NBIX) Receives a Buy from UBS

Cory Kasimov

Evercore ISI

$200

Buy

36.36%

Upside

Reiterated

09/19/25

Evercore ISI Sticks to Their Buy Rating for Neurocrine (NBIX)

Brian Abrahams

RBC Capital

$144→$149

Buy

1.59%

Upside

Reiterated

09/05/25

Neurocrine (NBIX) Receives a Buy from RBC Capital

Joshua Schimmer

Cantor Fitzgerald

$170

Buy

15.91%

Upside

Reiterated

09/04/25

Neurocrine (NBIX) Receives a Buy from Cantor Fitzgerald

Bryce Generon

TR | OpenAI - 4o

$145→$152

Buy

3.63%

Upside

Reiterated

08/19/25

AI Generated ArticleAI Generated Article

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Neurocrine

1 Month

xxx

Success Rate

15/24 ratings generated profit

Average Return

+0.97%

reiterated a xxx

rating 4 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 62.50% of your transactions generating a profit, with an average return of +0.97% per trade.

3 Months

xxx

Success Rate

19/28 ratings generated profit

Average Return

+4.15%

reiterated a xxx

rating 4 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 67.86% of your transactions generating a profit, with an average return of +4.15% per trade.

1 Year

Anupam RamaJ.P. Morgan

Success Rate

20/27 ratings generated profit

Average Return

+11.03%

reiterated a buy rating 4 months ago

Copying Anupam Rama's trades and holding each position for 1 Year would result in 74.07% of your transactions generating a profit, with an average return of +11.03% per trade.

2 Years

xxx

Success Rate

27/28 ratings generated profit

Average Return

+19.54%

reiterated a xxx

rating 4 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 96.43% of your transactions generating a profit, with an average return of +19.54% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NBIX Analyst Recommendation Trends

Rating

May 25

Jun 25

Jul 25

Aug 25

Sep 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, NBIX has received 53 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. NBIX average Analyst price target in the past 3 months is 168.73.

Each month's total comprises the sum of three months' worth of ratings.

NBIX Financial Forecast

NBIX Earnings Forecast

Next quarter’s earnings estimate for NBIX is $1.56 with a range of $1.14 to $2.06. The previous quarter’s EPS was $1.06. NBIX beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.14% of the time in the same period. In the last calendar year NBIX has Outperformed its overall industry.

NBIX Sales Forecast

Next quarter’s sales forecast for NBIX is $746.24M with a range of $709.40M to $788.24M. The previous quarter’s sales results were $687.50M. NBIX beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.49% of the time in the same period. In the last calendar year NBIX has Outperformed its overall industry.

NBIX Stock Forecast FAQ

What is NBIX’s average 12-month price target, according to analysts?

Based on analyst ratings, Neurocrine’s 12-month average price target is 168.73.

What is NBIX’s upside potential, based on the analysts’ average price target?

Neurocrine has 15.04% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is NBIX a Buy, Sell or Hold?

Neurocrine has a consensus rating of Strong Buy which is based on 22 buy ratings, 3 hold ratings and 0 sell ratings.

What is Neurocrine’s price target?

The average price target for Neurocrine is 168.73. This is based on 25 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $200.00 ,the lowest forecast is $124.00. The average price target represents 15.04% Increase from the current price of $146.67.

What do analysts say about Neurocrine?

Neurocrine’s analyst rating consensus is a Strong Buy. This is based on the ratings of 25 Wall Streets Analysts.

How can I buy shares of NBIX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Neurocrine (NBIX) Stock Forecast & Price Target

NBIX Analyst Ratings

NBIX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Neurocrine

NBIX Analyst Recommendation Trends

NBIX Financial Forecast

NBIX Earnings Forecast

NBIX Sales Forecast

NBIX Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts